Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease Sep 18, 2012
Navidea Biopharmaceuticals Receives Complete Response Letter from FDA for Lymphoseek® NDA Due to Manufacturing Deficiencies Sep 10, 2012
Navidea Biopharmaceuticals Names Pharma Industry Veteran Cornelia Reininger, M.D., Ph.D., as Chief Medical Officer Sep 5, 2012
Navidea Biopharmaceuticals Second Quarter 2012 Earnings and Business Update Conference Call Invitation Jul 30, 2012
Navidea Biopharmaceuticals Announces $50 Million Credit Facility with Platinum-Montaur Life Sciences Jul 26, 2012
